Cargando…
Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report
BACKGROUND: Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is a heterogeneous disease. To date, more than ninety ALK fusions in lung cancer have been found. Here, we report for the first time a rare LOC388942-ALK fusion in NSCLC was sensitive to crizotinib but resistant...
Autores principales: | Zhai, Xiaoqian, Liu, Yanyang, Liang, Zuoyu, Wang, Weiya, Qin, Tian, Liu, Stephen V., Um, Sang-Won, Luo, Feng, Liu, Jiewei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708479/ https://www.ncbi.nlm.nih.gov/pubmed/36467355 http://dx.doi.org/10.21037/atm-22-5194 |
Ejemplares similares
-
Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
por: Lei, Xi, et al.
Publicado: (2022) -
Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report
por: Gu, Xiaodong, et al.
Publicado: (2022) -
High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report
por: Li, Yan, et al.
Publicado: (2022) -
Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review
por: Piao, Mei-Na, et al.
Publicado: (2022) -
Locally advanced undifferentiated small round cell sarcoma of the lung with novel SDCCAG8-AKT3 fusion and type II tumor immunity in the microenvironment: a rare case report
por: Huang, Lin, et al.
Publicado: (2022)